MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation

Area of Science:

• Molecular Biology
• Cancer Research
• Cellular Degradation Mechanisms

Background:

• MCL1 (myeloid cell leukemia 1) is a key anti-apoptotic protein crucial for cell survival.
• Mechanisms regulating MCL1 degradation, especially in solid tumors, are not fully understood.
• Ubiquitylation and proteasomal degradation are known pathways for protein turnover.

Purpose of the Study:

• To elucidate the mechanisms driving MCL1 degradation in prostate cancer.
• To identify the specific ubiquitin ligase responsible for NOXA-mediated MCL1 degradation.
• To explore therapeutic strategies targeting MCL1 degradation for cancer treatment.

Main Methods:

• Utilized prostate cancer cell lines.
• Investigated the role of NOXA and integrated stress response in MCL1 regulation.
• Identified the ubiquitin ligase MARCH5 as a key mediator of MCL1 degradation.

Main Results:

• Increased NOXA, induced by kinase inhibitors activating the integrated stress response, promotes MCL1 degradation.
• MARCH5 (Membrane-Associated Ring-CH-Type Finger 5) was identified as the primary E3 ubiquitin ligase mediating NOXA-dependent MCL1 degradation.
• Enhancing MARCH5-mediated MCL1 degradation sensitizes cells to BCLXL-targeting BH3 mimetics, suggesting a therapeutic approach for solid tumors.

Conclusions:

• NOXA and MARCH5 are critical regulators of MCL1 degradation in prostate cancer.
• Targeting MARCH5-mediated MCL1 degradation represents a promising strategy to enhance apoptosis in solid tumors, particularly when combined with BCLXL inhibitors.
• A codependence between MARCH5 and MCL1 exists, exploitable even in tumors with genomic loss of MARCH5.